CompletedInterventionalPhase 2Last updated Mar 10, 2023

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

Post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 Matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies

Overview

ClinicalTrials.gov ID: NCT03270748
Lead Sponsor: Gruppo Italiano Trapianto di Midollo OsseoOTHER
Brief Summary: The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies.
Study Type

Status

Overall Status: Completed
Start Date: Jan 15, 2020Actual
Primary Completion Date: Nov 20, 2022Actual
Completion Date: Nov 20, 2022Actual

Study Record Dates

First Submitted: Aug 24, 2017
First Submitted that Met QC Criteria: Aug 30, 2017
First Posted: Sep 1, 2017Actual
Last Update Submitted that Met QC Criteria: Mar 9, 2023
Last Update Posted: Mar 10, 2023Actual
Last Verified: Mar 2023

NCT02294552Completed

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

NCT05289167Recruiting

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

NCT07675174Not yet recruiting

Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

NCT02360111Terminated

GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

NCT02065154Completed

Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis

NCT04503616Completed

Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention